fresco2 study: fda approval of fruquintinib for refractory colorectal cancer
Published 5 months ago • 1.4K plays • Length 14:59Download video MP4
Download video MP3
Similar videos
-
0:39
fda approval: #fruquintinib for #colorectalcancer
-
4:24
dr. cathy eng discusses fresco-2 trial and fruquintinib for colorectal cancer
-
4:48
fresco-2: phase iii study of fruquintinib in patients with mcrc
-
9:05
fresco-2: analyzing fruquintinib for refractory metastatic colorectal cancer
-
1:24
positive results& remaining questions in the fresco-2 study of colorectal cancer: 2022 esmo florida
-
3:35
#esmo22 highlights on the efficacy and safety of fruquintinib in refractory mcrc: the fresco-2 study
-
3:33
fruquintinib provides improvement in overall survival for refractory mcrc
-
3:15
investigating fruquintinib in patients with refractory metastatic crc
-
1:30
how will fruquintinib fit in the colorectal cancer treatment landscape?
-
9:41
dr. cathy eng discusses the fresco-2 study and its impact on metastatic colorectal cancer treatment
-
2:39
patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
-
2:27
fruquintinib in treating metastatic colorectal cancer
-
2:05
fruquintinib vs. placebo in mcrc: q-twist analysis from fresco-2
-
0:37
takeda’s fruzaqla (fruquintinib) gets fda nod for metastatic colorectal cancer
-
1:07
integrating fruquintinib into clinical practice in heavily pretreated crc
-
6:53
psmafore: methodology, nuances, and implications
-
1:15
asco22: chris manz, md on ai in oncology | dana-farber cancer institute
-
1:09
chemodx
-
11:23
how is cancer diagnosed? path 101